通讯作者: 贺正琼, hezhengqiong7879@163.com

DOI：10.12201/bmr.202608.00029

Clinical evidence mapping analysis of Chinese medicine external treatment for Mycoplasma pneumoniae pneumonia

• 摘要：目的 运用证据图谱系统分析中医外治法干预肺炎支原体肺炎（Mycoplasma pneumoniae pneumonia,MPP）的临床研究现状。方法 检索PubMed、Web of Science、Embase、Cochrane Library、中国知网（CNKI）、维普(VIP)、万方(WanFang)、中国生物医学文献服务系统(SinoMed)建库至2026年3月的相关研究。采用Cochrane RoB 2.0、AGREEⅡ分别评价随机对照试验和指南质量。采用文字结合气泡图、网络图、条形堆积图等可视化呈现。结果 研究热度在2025年达到峰值。样本量集中在75～115例。干预周期以1～2周为主。选用单种外治法为主，高频运用穴位贴敷（55.3%）。核心证型为痰热闭肺证（42.9%）。结局指标偏重临床疗效（82.2%）与临床症状/体征（63.8%），而中医证候积分（33.9%）、远期预后（3.9%）及生活质量（2.2%）等关注不足。方法学质量评价显示纳入RCTs偏倚风险高（54.5%）。结论 研究表明，中医外治法干预MPP具有效缩短病程、降低炎症反应等优势，但现有研究质量普遍不高，存在设计规范性不足、证据碎片化、结局指标维度单一问题，未来应推动多中心、大样本的高质量临床研究，为中医外治法干预MPP提供更高级别的循证依据。

  关键词： 支原体肺炎；中医外治法；证据图谱；可视化分析

   

  Abstract: Objective To systematically analyze the current status of clinical research on traditional Chinese medicine (TCM) external therapies for Mycoplasma pneumoniae pneumonia (MPP) using evidence mapping.Methods Relevant studies were retrieved from PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, WanFang, and SinoMed from database inception to March 2026. The Cochrane RoB 2.0 tool and AGREE II instrument were used to assess the methodological quality of randomized controlled trials (RCTs) and clinical guidelines, respectively. The evidence distribution was visualized using bubble charts, network diagrams, and stacked bar charts, supplemented by textual descriptions.Results Research interest peaked in 2025. Sample sizes were predominantly 75–115 cases, and intervention durations were mainly 1–2 weeks.Single external therapy was the main type of intervention, with acupoint application being the most frequently used (55.3%). The core TCM syndrome was phlegm-heat obstructing the lung (42.9%). Outcome indicators focused heavily on clinical efficacy (82.2%) and clinical symptoms/signs (63.8%), whereas TCM syndrome scores (33.9%), long-term prognosis (3.9%), and quality of life (2.2%) received insufficient attention. Methodological quality assessment showed that 54.5% of the included RCTs had a high risk of bias.Conclusion TCM external therapies for MPP have advantages in shortening the disease course and reducing inflammatory responses. However, the overall quality of existing studies is low, with issues such as inadequate design standardization, fragmented evidence, and a narrow scope of outcome indicators. Future high-quality, multi-center, large-sample clinical studies are warranted to provide higher-level evidence for TCM external therapies in MPP management.

  Key words: Mycoplasma Pneumonia；Chinese medicine external treatment；Clinical evidence mapping；Visualization

  提交时间：2026-08-13

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 王美林, 杨鹏丽, 庞高峰, 郭峥. 基于Citespace的中医药治疗肺炎支原体肺炎可视化分析. 2026. doi: 10.12201/bmr.202604.00142

  p>何海玲, 陆建良, 冯媛, 卢艳玲. 儿童重症肺炎支原体肺炎的临床特点分析. 2025. doi: 10.12201/bmr.202505.00038

  李美潼, 白晓红. 免疫失衡介导小儿支原体肺炎的中西医干预研究进展. 2026. doi: 10.12201/bmr.202608.00022

  吕海涛, 沈腾腾, 许会卿, 徐月波, 郑吉善. 多西环素治疗8岁以下儿童肺炎支原体肺炎的疗效分析. 2025. doi: 10.12201/bmr.202509.00001

  时小淋, 汤冬静, 吴美慧. 儿童肺炎支原体支气管肺炎和大叶性肺炎的相关危险因素分析. 2025. doi: 10.12201/bmr.202507.00035

  胡超海, 冯俊凯, 汪翼凡. 基于文献计量学和知识图谱的中医药治疗骨结核可视化分析. 2025. doi: 10.12201/bmr.202501.00039

  施明杰, 叶洪舟, 袁琛. 大环内酯类耐药肺炎支原体肺炎患儿发展为重症肺炎的危险因素分析及预测模型构建. 2024. doi: 10.12201/bmr.202409.00021

  李倩倩, 马紫阳, 方向明, 郭倩, 汪堃, 吴鹏, 叶卫东, 张越, 袁亚美. 基于CiteSpace和VOSviewer中医药治疗哮喘的可视化分析. 2025. doi: 10.12201/bmr.202506.00055

  陈昕, 杨晓彤, 李一凡, 纪伟. 中医药防治干燥综合征的可视化分析. 2025. doi: 10.12201/bmr.202502.00032

  王媛媛, 常艳美, 于丽娟, 孟淑萍. 肺炎支原体RNA检测在儿童肺炎支原体肺炎诊断和治疗中的价值研究. 2025. doi: 10.12201/bmr.202506.00025

• 序号	提交日期	编号	操作
  1	2026-05-26	10.12201/bmr.202608.00029V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论